Enzon Pharmaceuticals Inc represents values of innovation, commitment to scientific excellence, and a dedication to improving patient outcomes. With a corporate philosophy centered around research and development, Enzon Pharmaceuticals Inc aims to discover and develop novel therapies that address unmet medical needs. By leveraging its expertise and advancing cutting-edge technologies, the company strives to deliver transformative treatments for complex diseases. Enzon Pharmaceuticals Inc's commitment to delivering differentiated therapeutic solutions is reflected in its unwavering focus on scientific rigor, collaboration, and patient-centricity. Embracing its mission, Enzon Pharmaceuticals Inc continuously endeavors to make a positive impact on the lives of patients worldwide.

Enzon Pharmaceuticals Inc is primarily present in the United States. While its operations are primarily focused in the US, Enzon also has a presence in select international markets. However, its primary focus remains on the US market where it develops, manufactures, and commercializes pharmaceutical products.

Enzon Pharmaceuticals Inc has achieved several significant milestones. These include successful completion of clinical trials for its novel drug candidates, securing FDA approvals for key products, and establishing strategic partnerships with leading pharmaceutical companies. Additionally, Enzon Pharmaceuticals Inc has witnessed noteworthy advancements in research and development, resulting in the discovery of innovative therapies. These accomplishments have reinforced the company's position as a prominent player in the pharmaceutical industry. Overall, Enzon Pharmaceuticals Inc has demonstrated notable progress in its pursuit of developing groundbreaking healthcare solutions.

Enzon Pharmaceuticals Inc is a biopharmaceutical company that was founded in 1981. It specializes in developing and commercializing innovative therapies for life-threatening diseases. Throughout its history, Enzon Pharmaceuticals Inc has focused on advancing therapeutic options for patients with cancer, infectious diseases, and immune-mediated disorders. The company has a diverse portfolio of products and technologies, including proprietary technologies for protein delivery and targeted delivery systems. Enzon Pharmaceuticals Inc has also established collaborations and partnerships to enhance its research and development efforts. With its commitment to scientific advancements and patient care, Enzon Pharmaceuticals Inc has become a reputable player in the pharmaceutical industry.

The main competitors of Enzon Pharmaceuticals Inc in the market include Pfizer, Inc., Johnson & Johnson, AbbVie Inc., Bristol-Myers Squibb Company, and Roche Holding AG.

Enzon Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

Enzon Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapeutics for patients with rare diseases. Their business model centers around identifying unmet medical needs and leveraging their expertise in drug development to bring innovative treatments to market. Enzon Pharmaceuticals works collaboratively with research institutions, healthcare professionals, and patients to advance their pipeline of novel therapies. By combining cutting-edge science and clinical expertise, they strive to improve the lives of individuals suffering from rare diseases. Enzon Pharmaceuticals Inc is committed to making a meaningful impact in the pharmaceutical industry through their dedication to research, development, and patient care.

The P/E ratio cannot be calculated for Enzon Pharmaceuticals at the moment.

The P/S cannot be calculated for Enzon Pharmaceuticals currently.

The AlleAktien quality score cannot be calculated for Enzon Pharmaceuticals at the moment.

The revenue cannot currently be calculated for Enzon Pharmaceuticals.

The profit cannot currently be calculated for Enzon Pharmaceuticals.

Enzon Pharmaceuticals Inc is a biopharmaceutical company based in New Jersey that specializes in the development of innovative therapeutics. The company was founded in 1981 and focuses on the areas of cancer, infectious diseases, and autoimmune disorders. Enzon works on the development of proteins and antibodies to block or destroy disease-causing molecules or cells. Enzon has two main business segments: biopharmaceuticals and utility cell. The biopharmaceutical segment focuses on the research, development, and marketing of therapeutic agents derived from natural proteins or produced as recombinant proteins. The utility cell segment offers cell culture products that can be used for research and the therapeutics market. Enzon has several products on the market, including Adagen (pegademase bovine), an enzyme replacement therapy for patients with ADA deficiency, a rare genetic condition. Enzon also manufactures and markets a polyethylene glycol (PEG) formulation of interferon alpha, PEG-Intron. Enzon has a strategic alliance with pharmaceutical company Pfizer to utilize Enzon's PEG technology for the development of drugs to treat cancer and other diseases. Enzon is currently engaged in multiple projects in the field of cancer therapy, including a phase 1 study of a novel immunotherapy for patients with metastatic melanoma and a phase 1b study of a novel antibody-drug conjugate (ADC) therapy for patients with advanced breast cancer. Enzon is also working on the development of antibodies against CD19, a surface protein expressed on certain blood cancer cells. Enzon has a strong pipeline of new therapeutic approaches for a variety of diseases such as cancer, autoimmune disorders, and infections. The company pursues a strategy of collaboration and alliances with other leading pharmaceutical and biopharmaceutical companies to promote innovation and growth. Overall, Enzon offers a comprehensive approach to the development of biopharmaceuticals and is on track to become one of the leading companies in the fields of cancer, autoimmune disorders, and infections. With its strong pipeline, innovative technology, and extensive experience in the development of biopharmaceuticals, Enzon is positioning itself for future growth and success.

Enzon Pharmaceuticals pays a dividend of 0 USD distributed over payouts per year.

The dividend cannot currently be calculated for Enzon Pharmaceuticals or the company does not pay out a dividend.

The ISIN of Enzon Pharmaceuticals is US2939041081.

The WKN of Enzon Pharmaceuticals is 873997.

The ticker of Enzon Pharmaceuticals is ENZN.

Over the past 12 months, Enzon Pharmaceuticals paid a dividend of 0.18 USD . This corresponds to a dividend yield of about 148.76 %. For the coming 12 months, Enzon Pharmaceuticals is expected to pay a dividend of 0 USD.

The current dividend yield of Enzon Pharmaceuticals is 148.76 %.

Enzon Pharmaceuticals pays a quarterly dividend. This is distributed in the months of January, October, March, October.

Enzon Pharmaceuticals paid dividends every year for the past 0 years.

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

Enzon Pharmaceuticals is assigned to the 'Health' sector.

To receive the latest dividend of Enzon Pharmaceuticals from 10/15/2019 amounting to 0.12 USD, you needed to have the stock in your portfolio before the ex-date on 9/30/2019.

The last dividend was paid out on 10/15/2019.

In the year 2023, Enzon Pharmaceuticals distributed 0 USD as dividends.

The dividends of Enzon Pharmaceuticals are distributed in USD.